08:49 AM EST, 12/08/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday that it has dosed the first subjects in its phase 1/2a clinical trial of its investigational RNA interference therapeutic ARO-MAPT to treat tauopathies, including Alzheimer's disease.

The study aims to evaluate single and multiple doses of the therapy in healthy volunteers and multiple doses of ARO-MAPT in patients with early Alzheimer's disease, in parallel. Initial data for the first parts of the study is expected in H2 of next year, Arrowhead said.

The therapy uses a new proprietary delivery system that achieved blood-brain-barrier penetration and deep knockdown of target genes across the central nervous system after subcutaneous injection in preclinical studies, the company said.

Arrowhead shares were up 11% in recent premarket activity on Monday.